A randomized, double-blind, placebo-controlled, multi-center phase II study for the evaluation of efficacy and safety of CS-8958 in patients with influenza virus infection

Trial Profile

A randomized, double-blind, placebo-controlled, multi-center phase II study for the evaluation of efficacy and safety of CS-8958 in patients with influenza virus infection

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2016

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 24 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top